Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT2 | P31751 | 3/20 | 0.55 |
| ▸ | AKT1 | P31749 | 1/20 | 0.55 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
| ▸ | FEN1 | P39748 | 2/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.41 |
| ▸ | ILK | Q13418 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.40 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.40 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 2/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.39 |
| ▸ | CLK2 | P49760 | 1/20 | 0.38 |
| ▸ | HIPK1 | Q86Z02 | 1/20 | 0.38 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.38 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30823568 | 0.79 | AKT2 (0.59) | AKT2AKT1PDK2FEN1ADRA1D | |
| SCHEMBL28552255 | 0.79 | AKT2 (0.72) | AKT2AKT1PDK2FEN1ADRA1D | |
| SCHEMBL30823569 | 0.79 | AKT2 (0.59) | AKT2AKT1PDK2FEN1ADRA1D | |
| SCHEMBL3911134 | 0.76 | AKT2 (0.55) | AKT2AKT1PDK2FEN1IDO1 | |
| SCHEMBL20511659 | 0.76 | AKT2 (0.55) | AKT2AKT1PDK2FEN1IDO1 | |
| SCHEMBL17641537 | 0.76 | AKT2 (0.55) | AKT2AKT1PDK2FEN1ADRA1D | |
| SCHEMBL105445 | 0.76 | AKT1 (0.55) | AKT2AKT1PDK2FEN1IDO1 | |
| SCHEMBL20468195 | 0.76 | AKT2 (0.55) | AKT2AKT1PDK2FEN1IDO1 | |
| SCHEMBL541293 | 0.76 | FEN1 (0.57) | AKT2AKT1PDK2FEN1IDO1 | |
| SCHEMBL5380089 | 0.76 | AKT1 (0.55) | AKT2AKT1PDK2FEN1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10370386-B2 | Substituted quinolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2019-08-06 | — | — | US | disclosed |
| US-20180118757-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118757-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | AKT2 120/4885AKT1 45/4885PDK2 2371/4885 |
| US-10370386-B2 | Substituted quinolines as inhibitors of KRAS G12C | KRAS, NRAS, HRAS | AKT2 130/4885AKT1 53/4885PDK2 2949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.